It's a pleasure to welcome Chief Medical Officer from Radiopharm Theranostics, Dr. Dimitris Voliotis. Radiopharm has a portfolio of both imaging and therapy radiopharmaceuticals in development. Of these, by far the most advanced is its imaging agent for detection of metastatic disease from primary cancers once these spread to the brain. RAD101 is a radiolabeled small molecule targeting fatty acid synthesis. In clinical trials, the drug has demonstrated outstanding efficacy in the detection of tumor regrowth following external beam radiation. The company's now preparing the drug for a phase III pivotal study and is expected to partner with a large pharma group in order to complete the study, and we believe there is a very compelling business case to entice potential partners.
The market for suspected metastases from brain cancer is estimated at 300,000 patients per year in the U.S. alone, and we believe this indication will be well reimbursed with reimbursement of at least AUD 5,000 per scan. Welcome, Dimitris, and thanks for joining us all the way from New Jersey, where it is still Thursday evening. Hello.
Thank you. Hi, and thanks, and welcome to everybody. Thanks for having me.
Yeah, it's great to have you again, Dimitris. You've got a slide presentation. Let's take a few minutes to run through that, and we'll come back and have a Q&A session afterwards.
Excellent. Thanks a lot. Notice and disclaimers. This is the overview of the pipeline. Our focus is on therapeutics, but the diagnostics are very, very important for us from a platform perspective and also from a partnering perspective. We have a differentiated platform with four clinical stage therapeutic assets. We have near-term catalysts, and the two imaging agents just finished successfully a phase II-B and a phase I, respectively. We will discuss RAD202, which is our nanobody in HER2-positive malignancies, RAD204, which is the PD-L1 targeting nanobody in PD-L1 positive malignancies. I will briefly say where we are from a study perspective with the B7-H3 antibody and the KLK3 antibody, but we do not have results for those yet. Let's go to the overview again. The four therapeutic compounds are in phase I. RAD202 and RAD204 are in Australia. RAD402 is also in Australia, exclusively in clinical development.
RV-01 is in the U.S. All these compounds are in phase I. RAD202, which is the HER2 targeting, is more advanced, as is RAD204. You will see that we are in later cohorts compared to the B7-H3 and the KLK3, which are still in the early cohorts. RAD101 just finished successfully the phase II-B. We had a very successful presentation last weekend at the Society for Neuro-Oncology in Philadelphia, and the RAD301 is the imaging agent for pancreatic cancer, which has also successfully completed the phase I study. Let's start with the imaging agents, first and foremost, RAD101. This is a first-in-class PET tracer, which we believe has a very high probability of success with near-term value and options for us. There is a very high unmet medical need. MRI is not sufficient in detecting suspected relapse after stereotactic radiosurgery. The market, as already mentioned, is very significant.
This is a first-in-class PET tracer, meaning we have a differentiated mechanism of action that we are targeting, and we have already reported this successful phase II-B readout earlier this year. As I said, the study was presented at a major congress just a few days ago. These are the milestones, the project milestones. We had a positive and very supportive advisory board in May, following which we put together our draft protocol and submitted that to the U.S. FDA for an end-of-phase II meeting, what is called an end-of-phase II meeting. We had a very positive discussion with them. We received the final minutes on November 1st. We have full alignment with the FDA on the protocol itself, on all the key aspects, the size, the endpoints, the statistical analysis, and we think we can start the study in Q1 of next year.
It is a single registrational phase III trial, not too large. For oncology, this is actually a very small one, being that it is a diagnostic study. The primary endpoints, as it is usual in diagnostic studies, are diagnostic accuracy, which are the sensitivity and specificity at the patient level. We have a signed contract with Siemens PETNET, which means that we have one of the world's most experienced companies in supply and logistics and radiolabeling and distribution with them. Obviously, something that is needed for a multi-center study that we will have. The primary endpoint was concordance with MRI. We have successfully, very successfully achieved that with a very high 93% concordance. The sensitivity thus far from the interim analysis in June was also very high with 86%. We did not yet have enough events for the specificity.
We have the primary endpoint met with this w hich is the concordance with the MRI, and we have an update on the sensitivity and the specificity readout expected by the end of this year, with a report possible at the very beginning of next year. In other words, the study is positive, and it provides the basis for us as a proof of concept to go into phase III. As I said, the study was presented by the Principal Investigator, Dr. Kulkarni, this week at SNO Annual Meeting, Society for Neuro-Oncology, and I am just showing you here the conclusion from that presentation. It was very, very well received. The interim results, as I said, show high agreement with a very good sensitivity, very high sensitivity of 86%.
No serious treatment-emergent adverse events in any of the 32 participants, and that means that these findings clearly support the continued clinical evaluation of the agent in patients with previously radiated brain metastases. Very positive. I had personally meetings with a number of KOLs, about 10, and people were very eager and very supportive of such a trial. They confirmed there is a huge unmet medical need, and they were very eager to participate in such a trial. So, very, very positive feedback. RAD301, that is the agent that is targeting pancreatic cancer or non-small cell lung cancer as a diagnostic. This is also a high unmet need, where the CT and MRI are falling short. This is a potential first-in-class PET tracer, targeting alpha v beta six, which is an antigen that is expressed highly in pancreatic cancer and other malignancies. Pancreatic cancer alone is a very good market.
So, clearly, from a diagnostic perspective, also a very, very important potential asset for phase II, and the phase II was positive in terms of the readouts that we had. So, this is also partnering-ready to go to the next phase. These were the imaging agents, so let us go now to the therapeutics, starting with the first, which is the RAD202 HER2-targeted radiotherapy. This is what is called a nanobody. It is a smaller format than a full-size antibody, so it has very good tumor penetration. HER2, of course, is a very much established target. It is one of the most important tumor targets in the world in oncology with breast cancer, but also other indications like gastric cancer, being HER2 positive, at least a certain percentage of the patients.
We hope that beyond the HER2 positive, we can expand this also then in HER2, what is called HER2 low and very low populations. In other words, in patient populations with a lower-than-usual expression of the antigen. The market that we are targeting, or the clinical indication, I should say, is patients after relapse, after current HER2-targeting antibody-drug conjugates. Based on the fact that this is a validated biology and we are using a MOA that is not cross-reactive with chemotherapy, we believe we have potential for best in class here. The study is very well advanced. We are in dose level four with 180 millicurie. We see really good tumor uptake. We see good safety.
We didn't have any DLTs thus far. We will be able to close or finish, I should say, the dose level four at the 180 and go to the next dose level five, probably at the 240. Just an example of what the drug can do in patients with breast cancer here. This is a patient with breast cancer with HER2 positive. This is an ampullary cancer, which is somewhat close to pancreatic cancer, not quite, but the patient was, of course, HER2 positive. You can see that with a good uptake, the patient had an 11% reduction in tumor size and was stable from a clinical perspective, stable disease. Again, very positive thus far, very good uptake.
We're very excited about this. With the next cohort going into higher dose levels at or around 240, we'll be able to test really a higher and hopefully clinically active dose. Again, looking at this from an investment case perspective, this is one of the largest, if not the largest, validated oncology targets. Radiotherapy introduces a new MOA. Where we are from today's perspective, while it is still early and we are in dose escalation, we do think we are trending towards standard of care outcomes. Next up is RAD204, that's the PD-L1 targeting radiotherapy. The principle is the same. This is a nanobody also. This one is targeting a different antigen, of course, PD-L1, an immune checkpoint inhibitor. The lead indication here is post-immunotherapy non-small cell lung cancer, but we do include all other tumors as long as they have some degree of PD-L1 expression.
Again, we're using a proven target, in this case PD-L1, introducing a new therapeutic modality that is not cross-resistant with chemotherapy or antibody-drug conjugates. The compound is in dose level three. As you can see here, we have not observed DLT so far. In that dose level of 90, we have observed one partial response, so we have clear patient benefit. As you can see on the right slide, taking it from top to bottom, I think you can easily see that there is a much smaller white area on the left hand of your slide. This is the patient's chest area with the tumor on the left of the slide. Everything that's white is tumor and associated changes. You can see that from baseline to first, second, and then onto the third dose, there's a clear reduction of the tumor and the associated changes.
This is clinical benefit. This is what we call a confirmed RECIST partial response with 43% tumor size reduction in a patient where we would expect essentially nothing. The patient has experienced also progression-free survival of over nine months. This is what we call a swimmer lane plot. What you can see is that we have three lanes that are all at or above six months, the first blue and the green underneath. This means that we have patients that have been on treatment, in this case, for six months or longer. Given, again, that this is still early days in the dose escalation, this is a great success. When we look again at the tumor size, just from a little different perspective, on the left side is what we call a waterfall plot.
This shows the best response at any time, and you can see on the right side, these are tumors that are shrinking. We have a few of those. Again, keep in mind, this is still low dose. On the right side, on the spider plot, you can see that everywhere where the line goes down, we have a reduction in tumor size, and a few of those or stabilization, and a few of those, as already mentioned in the discussion of the swimmer plot, are indeed there for quite a bit of time. Summarizing where we are with this from a clinical perspective, we're trending again towards some better results than standard of care with one PR. At this point, we have still 50% response rate with a PFS of 6.7 months.
The standard of care in this line of treatment would be much less, 20%-25%, with an average PFS of four to six months. Summarizing the investment case, this is, as it is, HER2, one of the largest and most validated tumor targets. It is certainly the largest, most validated immuno-oncology target, with a very large addressable market, as you can see here. Targeted radiotherapy introduces a very new principle, combining checkpoint inhibition and radiotherapy. Those two are synergistic. It is a platform, and it enables continued optimization for this agent and for the pipeline. We have early clinical signal observed in one patient with a PR, and we are first in class with this. There is no other radiopharmaceutical, targeted radiopharmaceutical in this space. B7-H3 targeting RV-01 and KLK3 targeting RAD402 are ongoing.
As already mentioned, they are in earlier stages of the dose escalation phase I and dose level two in each case. Enrollment is progressing really well. We are obviously evaluating the results. We cannot share them yet. It is early days, but from an operational perspective, these trials are advancing very, very well. To close and summarize, we believe that the two imaging assets provide very great opportunity for value creation for partnering. That partnering process is ongoing. For the therapeutics, we are really focusing our efforts and our resources on the inflection points. The two nanobody will have inflection points that we can discuss in the first half of 2027, and RV-01 and RAD402, the full-size antibodies against B7-H3 and KLK3 in the second half of next year. Thank you with that, and I am happy to take any questions.
Yeah. Thanks, Dimitris. That was a great run through. Very comprehensive. Just want to come back to RAD101 for a few moments. You said 86% sensitivity, and you're still waiting on the final specificity. But really, the data is out there now. You've got everything you need to undertake partnering discussions on this asset. Just heading into that post-study meeting with the FDA, what was the tone of the FDA, and do you think that they're supportive of this drug coming to market?
It was a very collegial, a very collaborative meeting. The FDA, there's no such tracer available.
Yeah.
It is a huge unmet medical need. The FDA is very eager to get such a drug approved, so they were very helpful and tried really to make it as easy as possible for us. We had very positive and constructive discussions. They're very supportive.
Now, I think that RAD101, just correct me if I'm wrong here, has that got breakthrough designation already?
Yes.
Yes.
It does.
Okay. That's a major incentive. Once you get the data—
No, I'm sorry. It doesn't have breakthrough. I apologize.
I thought I read that it did.
It has fast track.
Okay. Nevertheless, that is still very positive. 86% sensitivity, so it is very accurate in the detection of disease, and you are waiting on a bit more data to confirm sensitivity, but look, the specificity rather. The sensitivity is the key measure here. You want to be able to detect tumor regrowth early, and what does that then allow physicians to do for these patients?
We have good examples from the study where you could show that the RAD101 was able to detect disease earlier than the standard of care MRI. That means that patients can be treated earlier with surgery or with another radiotherapy. Early treatment of tumors that are small enough that they can receive potentially, I do not want to say curative, but radiotherapy that can eradicate that particular tumor is obviously very important. The bigger the tumor becomes, the more difficult it is to treat them. Detecting them at an early stage means you can really treat them very effectively.
You got 300,000 patients a year in the U.S. alone who have primary cancers that spread to the brain. That is your low-hanging fruit, if you like. If you get one scan per patient, say, that makes it into a very attractive commercial market.
I don't think it would be one scan. I mean, this is a patient population that is routinely receiving scans every three months.
Yeah.
With a phase III that, as I believe will be successful, I truly believe that they would receive, together with the MRI, a PET scan every three, four, five months, whenever the patient is up for a re-scan or for re-evaluation. It would not be just one scan per patient's lifetime. It would be multiple.
The other thing that indicates to me that this is going to be a success, this trial was recruited, it was only 30 patients, but nevertheless, it was recruited very, very quickly. You mentioned in your presentation also that you had a number of KOLs at the recent congress coming up to you and expressing interest in participating in the approval study. That's a good sign as well.
That's a tremendously good sign. It's now very positive. Again, this is something that is a huge unmet need. We, I think, will be able to fill that unmet need. I think it could really very change the treatment of these patients in a very significant positive way, enabling us an earlier detection. Just to give you an example, we had one patient where the PET was able to detect the metastases four months before the MRI.
Then we had another patient where the MRI was read as necrosis, but our scan showed that there was viable tumor in there. In other words, what they thought was necrosis is tumor, so they have to treat it now.
Yeah. So that is great. Now, I know you are a scientist and not necessarily focused on the commercialization of these assets, but this is going to be a very attractive asset for a development partner. Just to be clear, I do not think there is any contention that you are looking for a development partner to take this through to the approval study.
Absolutely. I think it is very important for us to have such a partner, and I think it is a very attractive asset. We are in active discussions here, and I am really looking forward to get this going.
Yeah, it should be a really exciting period. Just flicking on to some of your other assets. So, what are you most excited about amongst the rest of the portfolio?
I mean, it's hard to say. I think they're all tremendously important and potentially value generating, but RAD202, the HER2 targeting nanobody is really advanced.
Yeah.
I am excited about that specifically because we are now in a higher dose level already, the 180 millicurie. We see very nice uptake, very nice tumor uptake. So obviously, being a clinician, I am excited about stuff that seems to work well. Doesn't mean that the others don't work, but this is more advanced, and I'm very excited about that.
Yeah.
Likewise, the 204 has also great potential.
Yeah.
And others that come behind it. RAD202 is in a really good place right now.
So, 202, you mentioned in your presentation you had one patient there where you saw at least stable disease. That is at the 180 millicurie doses. You are going up to the 240 prospectively in your fifth cohort there. Pretty exciting times. You should start to see some further efficacy at that dose level, I would imagine.
I cannot really say.
Yeah.
We may have to go even higher than that. As long as we, again, we have not seen a single DLT.
Yeah.
Right? From a safety perspective, this is just fantastic. We will increase the dose as long as we can, and when we start seeing clinical responses, hopefully that will be an indication of having the right dose.
Yeah. This is in patients who are, is it breast cancer or is it GI patients that you've been dosing?
It is HER2 positive patients, so we have breast, we have GYN malignancy.
Okay. Well, everyone.
All cancers. But we see really good results in breast cancer, for example.
Okay. Well, look, that has been a great run through, Dimitris. Thank you very much for your time this evening, where it is, where you are in New Jersey. We look forward to seeing you again soon.
Thank you.
You are welcome. We are going to take a short break. On the other side of that, Martyn Jacobs will be back with EBR. Thank you.
Bye.